WO2025004002 - TREATMENT OF POMPE DISEASE
National phase entry is expected:
Publication Number
WO/2025/004002
Publication Date
02.01.2025
International Application No.
PCT/IB2024/056362
International Filing Date
28.06.2024
Title **
[English]
TREATMENT OF POMPE DISEASE
[French]
TRAITEMENT DE LA MALADIE DE POMPE
Applicants **
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventors
BOYANAPALLI, Ruby
MOORE, Simon
Priority Data
63/511,367
30.06.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 7435 | |
| EPO | Filing, Examination, Granting | 174175 | |
| Japan | Filing, Examination, Granting | 5339 | |
| South Korea | Filing, Examination, Granting | 12071 | |
| USA | Filing, Examination, Granting | 40290 |
Total:
239,310
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Variant acid alpha-glucosidase (GAA) polypeptides, codon-optimized polynucleotides encoding GAA, and GAA gene therapy methods and constructs are provided.[French]
L'invention concerne des polypeptides d'alpha-glucosidase acide (GAA) variants, des polynucléotides optimisés par codons codant pour GAA, ainsi que des méthodes et des constructions de thérapie génique à GAA.